Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience
Authors' conclusion
SCIG is preferred by most patients over IVIG without a substantial increased disease activity or need for additional CS.
Study context
- Population
- Consecutive patients with IIM transitioned from IVIG to subcutaneous immunoglobulin (SCIG) therapy for >12 months, single centre
- Participants
- 20 patients
- Exposure
- SCIG vs prior IVIG
- Outcome
- Patient preference and effectiveness after transition from IVIG to SCIG
Methodological detailssingle-centre, real-world, pre-post comparison (12 months pre- and post-SCIG initiation), Patient preference surveyed using a questionnaire previously used in studies of neuroinflammatory conditions
- Single-centre
- Real-world
- Pre-post comparison (12 months pre- and post-SCIG initiation)
- Patient preference surveyed using a questionnaire previously used in studies of neuroinflammatory conditions
Main finding
As reported in the abstract
Preferred SCIG over IVIG
78.9%
Observational data: associations, not effects.
Further findings
| Outcome | Pre-SCIG | Post-SCIG |
|---|---|---|
| Global disease activity (MITAX) · 12 months pre- and post-SCIG initiation | 3.31 | 3.02 |
Global disease activity (MITAX) · 12 months pre- and post-SCIG initiation
- No significant difference
Cumulative steroid doses · 12 months pre- and post-SCIG initiation
- No significant difference
Disease flares and changes in immunosuppression
- Patients with disease flares
- 3
- Patients escalated in immunosuppression
- 5
- Patients de-escalated in immunosuppressive medications
- 4
Original publication
Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience. Rheumatology (Oxford). Published 5 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →